TLSI Stock News & Catalysts – TriSalus Life Sciences

FEATURED

TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum

TriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients

Summary

Oct 29, 2026, 4:05 PM ·Business Wire

RECENT

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform

Oct 20, 2026, 4:32 PM ·Business Wire

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform

Sep 22, 2026, 4:15 PM ·Business Wire

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

Aug 31, 2026, 4:05 PM ·Business Wire

TriSalus Life Sciences Reports Second Quarter 2026 Results

Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting

Aug 6, 2026, 4:05 PM ·Business Wire

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Jul 29, 2026, 4:05 PM ·Business Wire

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

Jul 16, 2026, 4:05 PM ·Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI). Such investors are

Jun 23, 2026, 5:45 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI). Such investors are advised

Jun 18, 2026, 10:00 AM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI). Such investors are advised to

Jun 16, 2026, 5:31 PM ·Globe Newswire

TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TriSalus Life Sciences, Inc.

Jun 10, 2026, 10:04 AM ·Globe Newswire

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share

Jun 10, 2026, 8:00 AM ·Business Wire

TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc.

ATLANTA, June 05, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether TriSalus Life Sciences, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI) complied with federal securities laws. On May 12,

Jun 5, 2026, 11:39 AM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI). Such investors are advised

Jun 4, 2026, 10:00 AM ·PRNewswire

TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareh

Jun 3, 2026, 6:00 AM ·Business Wire

TriSalus Life Sciences, Inc. TLSI · News